Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42174   clinical trials with a EudraCT protocol, of which   6938   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-001521-27
    Sponsor's Protocol Code Number:SP-1011-003
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2020-02-28
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2019-001521-27
    A.3Full title of the trial
    Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects with Eosinophilic Esophagitis
    Formulación de comprimidos orales dispersables de propionato de fluticasona en la esofagitis eosinofílica: Estudio de dos partes, aleatorizado, doble ciego y controlado con placebo de APT-1011 en sujetos adultos y adolescentes con esofagitis eosinofílica.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study with Eosinophilic Esophagitis subjects
    Estudio en sujetos con esofagitis eosinofílica.
    A.3.2Name or abbreviated title of the trial where available
    FLUTE-2
    A.4.1Sponsor's protocol code numberSP-1011-003
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAdare Pharmaceuticals US, LP
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAdare Pharmaceuticals US, LP
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAdare Pharmaceuticals US, LP
    B.5.2Functional name of contact pointPeter C. Richardson
    B.5.3 Address:
    B.5.3.1Street AddressPrinceton Pike Corporate Center, 1200 Lenox Drive, Suite 100
    B.5.3.2Town/ cityLawrenceville, New Jersey
    B.5.3.3Post code08648
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1609450 1312
    B.5.5Fax number+1609896 1404
    B.5.6E-mailPeter.Richardson@adarepharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/16/1815
    D.3 Description of the IMP
    D.3.1Product nameAPT-1011
    D.3.2Product code APT-1011 - 3 mg
    D.3.4Pharmaceutical form Orodispersible tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFluticasone Propionate, USP
    D.3.9.1CAS number 80474-14-2
    D.3.9.2Current sponsor codeAPT-1011
    D.3.9.3Other descriptive nameFLUTICASONE PROPIONATE
    D.3.9.4EV Substance CodeSUB02241MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboOrodispersible tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Eosinophilic Esophagitis
    Esofagitis eosinofílica.
    E.1.1.1Medical condition in easily understood language
    Eosinophilic Esophagitis
    Esofagitis eosinofílica.
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10064220
    E.1.2Term Eosinophilic esophagitis
    E.1.2System Organ Class 100000004856
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Part A co-primary objectives:
     To compare the Week 12 histologic responder rates (≤ 6 peak eosinophils [eos]/high power field [HPF]) from baseline for APT-1011 3 mg hora somni (HS) with that for placebo. HPF will be defined as a standard area of 235 square microns in a microscope with 40x lens and 22mm ocular
    To compare mean change in number of dysphagia episodes from baseline to Week 12 for APT-1011 3 mg HS with that for placebo
    Part B key objectives:
    To compare the Week 52 histologic relapse-free rates (≤ 15 peak eos/HPF) for APT-1011 responders randomized to continuing APT-1011 3 mg HS (maintenance) with responders randomized to placebo (withdrawal of APT-1011 3 mg HS)
    See the entire list in the protocol section Objectives in Page 4
    Objetivos coprincipales de la parte A:Comparar las tasas de sujetos con respuesta histológica de la semana 12 (≤6 picos de [eos]/campo de gran aumento [CGA]) con respecto al inicio de APT-1011 3 mg hora somni (al irse a dormir, HS) con el del placebo. El CGA se definirá como un área estándar de 235 micrones cuadrados en un microscopio con una lente de 40x y un ocular de 22 mm.Comparar el cambio medio en el número de episodios de disfagia desde el inicio hasta la semana 12 de APT-1011 3 mg HS con el de placebo
    Objetivos principales de la parte B:Comparar las tasas sin recidiva histológica de la semana 52 (≤15 picos de eos/CGA) de los sujetos con respuesta para APT-1011 aleatorizados para continuar con APT-1011 3 mg HS (mantenimiento) con los sujetos con respuesta aleatorizados a placebo(retirada de APT-1011 3 mg HS).
    Refiéranse a lista completa que se encuentra en el Protocolo en la sección Objetivos en la página 4
    E.2.2Secondary objectives of the trial
    Part A secondary objectives
     To compare endoscopic appearance evaluated by the mean change from baseline to Week 12 in REFs for APT-1011 3 mg HS with that for placebo
    To compare the percentage of subjects with <1 peak eos/high power field at Week 12 for APT-1011 3 mg HS with that for placebo.
    Part B secondary objectives
     To compare endoscopic appearance evaluated by the mean change from Week 12 to the first esophagogastroduodenoscopy (EGD) conducted in Part B (at or prior to Week 52) in EREFs for APT-1011 responders randomized to continue APT-1011 3 mg HS with responders randomized to placebo (withdrawal of APT-1011 3 mg HS)

    See the entire list in the protocol section Objectives in Page 4
    Objetivos secundarios de la parte A:
    Comparar el aspecto endoscópico evaluado por el cambio medio desde el inicio hasta la semana 12 en la puntuación de referencia endoscópica de la esofagitis eosinofílica (Eosinofhilic Esophagitis Endoscopic Reference Score, EREFs) del tratamiento con APT-1011 3 mg HS con el del placebo.
    Comparar el porcentaje de sujetos con <1 pico de eos/campo de gran aumento en la semana 12 de APT-1011 3 mg HS con el del placebo.

    Objetivos secundarios de la parte B:
    Comparar el aspecto endoscópico evaluado por el cambio medio desde la semana 12 hasta la primera esofagogastroduodenoscopia (EGD) realizada en la Parte B (en la semana 52 o antes) en la EREFs de los sujetos con respuesta a APT-1011 aleatorizados para continuar con APT-1011 3 mg HS con el de los sujetos con respuesta aleatorizados a placebo (retirada de APT-1011 3 mg HS).
    Refiéranse a lista completa que se encuentra en el Protocolo en la sección Objetivos en la página 4
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Adult male or female ≥15 years of age at the time of informed consent or assent
    2. Each subject and/or their parents or legal guardian (for adolescents), must read, understand and provide consent or assent together with their parent(s) or guardian signature (for adolescents) on the ICF for this study and be willing and able to adhere to study-related treatment regimens, procedures and visit schedule
    3. Diagnosis or presumptive diagnosis of EoE that is confirmed during the Screening period by histology that demonstrates ≥15 peak eos/HPF. In order to ensure that a diagnosis can be made, at least 5–6 biopsies should be taken including both proximal and distal specimens (~3 each). Mid-esophageal biopsies are optional. HPF will be defined as a standard area of 235 square microns in a microscope with 40x lens and 22mm ocular.
    a) Esophagogastroduodenoscopies and biopsies are to be obtained during the Screening period
    b) Biopsies will be read by a central pathologist
    c) Esophagogastroduodenoscopies and biopsies performed outside the study will not be accepted to meet eligibility criteria
    d) Optional biopsies may be taken and processed locally for local use, if specified in the local ICF. If serious pathology is unexpectedly encountered biopsies of such lesions must be processed locally
    4. Have a subject-reported history of ≥6 episodes of dysphagia in the 14 days prior to baseline
    5. Completion of the daily diary on at least 11 out of the 14 days during the 2-week Baseline Symptom Assessment
    Criterios de inclusión:
    1. Hombres o mujeres adultos ≥15 años en el momento del consentimiento informado o asentimiento
    2. Cada sujeto y/o sus progenitores o tutor legal (para adolescentes) debe leer, comprender y facilitar el consentimiento o asentimiento junto con la(s) firma(s) de su(s) progenitor(es) o tutor (en el caso de adolescentes) en el FCI para este estudio y estar dispuesto y ser capaz de cumplir con los regímenes de tratamiento, los procedimientos y el calendario de visitas relacionados con el estudio
    3. Diagnóstico o presunción de diagnóstico de EE confirmado durante la fase de selección por histología que demuestre ≥15 picos de eos/CGA. Para garantizar que se pueda realizar un diagnóstico, se deben tomar al menos 5–6 biopsias que incluyan muestras tanto proximales como distales (~3 cada una). Las biopsias esofágicas de la zona central son opcionales. El CGA se definirá como un área estándar de 235 micrones cuadrados en un microscopio con lente 40x y ocular de 22 mm.
    a) Se deben obtener esofagogastroduodenoscopias y biopsias durante la fase de selección
    b) Las biopsias serán leídas por un anatomopatólogo central
    c) Las esofagogastroduodenoscopias y las biopsias realizadas fuera del estudio no se aceptarán para cumplir los criterios de aptitud
    d) Pueden realizarse y procesarse localmente biopsias opcionales para su uso local, si se especifica en el FCI local. Si se encuentra inesperadamente una patología grave, las biopsias de dichas lesiones deben procesarse localmente
    4. Tener antecedentes notificados por el sujeto de ≥6 episodios de disfagia en los 14 días previos al inicio
    5. Cumplimentación del diario al menos 11 de cada 14 días durante la evaluación de los síntomas inicial de 2 semanas
    E.4Principal exclusion criteria
    1. Have known contraindication, hypersensitivity, or intolerance to corticosteroids
    2. Have a contraindication to, or factors that substantially increase the risk of, EGD procedure or esophageal biopsy or have narrowing of the esophagus that precludes EGD with a standard 9 mm endoscope
    3. Have history of an esophageal stricture requiring dilatation within the previous 12 weeks prior to Screening
    4. Bone age more than 12 months behind chronological age for adolescent subjects
    5. Have any physical, mental, or social condition or history of illness or laboratory abnormality that in the Investigator’s judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study or increase the safety risk to the subject such as uncontrolled diabetes or hypertension or may increase risk of corticosteroid toxicity (e.g. abnormal bone mineral density)
    6. History or presence of oral or esophageal mucosal infection whilst using inhaled or nasal corticosteroids
    7. Have any mouth or dental condition that prevents normal eating
    8. Have any condition affecting the esophageal mucosa or altering esophageal motility other than EoE, including erosive esophagitis (grade B or higher as per the Los Angeles Classification of Gastroesophageal Reflux Disease; hiatus hernia longer than 3 cm, Barrett’s esophagus, and achalasia)
    9. Use of systemic (oral or parenteral) corticosteroids within 60 days before Screening, use of swallowed corticosteroids within 30 days before Screening
    10. Initiation of either inhaled or nasal corticosteroids or high-potency dermal topical corticosteroids within 30 days before Screening
    11. Use of calcineurin inhibitors or purine analogues (azathioprine, 6-mercaptopurine) in the 12 weeks before Screening
    12. Use of potent cytochrome P450 (CYP) 3A4 inhibitors (eg, ritonavir and ketoconazole) in the 12 weeks before Screening
    13. Initiation of an elimination diet or elemental diet within 30 days before Screening (diet must remain stable after signing ICF)
    14. Morning (07:00 to 09:00, or as close to that window as possible) serum cortisol level ≤5 μg/dL (138 nmol/L) that is not responsive to ACTH stimulation: defined as a serum cortisol level <16 μg/dL (440 nmol/L) at 60 minutes with ACTH stimulation test using 250 μg cosyntropin administered intramuscularly (ie, an abnormal result on the ACTH stimulation test)
    15. Use of biologic immunomodulators in the 24 weeks before Screening (allergy desensitization injection or oral therapy is allowed as long as the course of therapy is not altered during the study period)
    16. Subjects who have initiated, discontinued, or changed dosage regimen of histamine H2 receptor antagonists, antacids or antihistamines for any condition such as gastro-esophageal reflux disease within 4 weeks before qualifying endoscopy. If already receiving these drugs, the dosage must remain constant throughout the study
    17. Subjects who have changed dosage regimen of PPIs within 8 weeks before qualifying endoscopy. If already receiving PPIs, the dosage must remain constant throughout the study
    18. Infection with hepatitis B, hepatitis C, or human immunodeficiency virus
    19. Have gastrointestinal bleeding or documented active peptic ulcer within 4 weeks prior to Screening or entering a new study period
    20. Have chronic infection such as prior or active tuberculosis, active chicken pox or measles or absence of prior measles, mumps and rubella vaccine. Subjects with tuberculosis exposure or who live in high endemic areas should be assessed locally for tuberculosis before consideration for the study
    21. Have immunosuppression, immunodeficiency, malignancy except treated
    22. Non-melanoma skin cancer, or known severe bleeding disorder
    23. Have a history or presence of Crohn’s disease, celiac disease, or other inflammatory disease of the gastrointestinal tract, including eosinophilic gastroenteritis
    24. Have current drug abuse in the opinion of the Investigator.
    25. Have current alcohol abuse in the opinion of the Investigator.
    26. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study

    Please refer to the complete list of the exclusion criteria in the protocol section "selection of subjects" in page 7
    Criterios de exclusión:
    1. Tener contraindicaciones, hipersensibilidad o intolerancia conocidas a los corticoesteroides 2. Tener contraindicación o factores que aumenten sustancialmente el riesgo de intervención de EGD o biopsia esofágica o que tengan estrechamiento del esófago que impida la EGD con un endoscopio estándar de 9 mm
    3. Tener antecedentes de estenosis esofágica que requiera dilatación en las 12 semanas anteriores a la selección 4. Edad ósea más de 12 meses por debajo de la edad cronológica en el caso de sujetos adolescentes 5. Tener cualquier afección física, mental o social o antecedentes de enfermedad o anomalía en el análisis que, a juicio del investigador, pueda interferir en los procedimientos del estudio o en la capacidad del sujeto de cumplir y completar el estudio o aumentar el riesgo de seguridad para el sujeto, como diabetes no controlada o hipertensión o que pueda aumentar el riesgo de toxicidad por corticosteroides (por ejemplo, densidad mineral ósea anómala) 6. Antecedentes o presencia de infección de la mucosa oral o esofágica mientras se utilizan corticoesteroides inhalados o nasals 7. Tener alguna afección bucal o dental que impida la alimentación normal
    8. Tener cualquier afección que afecte a la mucosa esofágica o altere la motilidad esofágica distinta a la EE, incluida la esofagitis erosiva (grado B o superior según la Clasificación de Los Ángeles de la enfermedad de reflujo gastroesofágico)21, hernia de hiato de más de 3 cm, esófago de Barrett y acalasia 9. Uso de corticoesteroides sistémicos (orales o parenterales) en los 60 días anteriores a la selección, uso de corticoesteroides deglutidos en los 30 días previos a la selección 10. Inicio de corticosteroides inhalados o nasales o corticoesteroides tópicos dérmicos de alta potencia en los 30 días anteriores a la selección
    11. Uso de inhibidores de la calcineurina o análogos de la purina (azatioprina, 6-mercaptopurina) en las 12 semanas anteriores a la selección 12. Uso de inhibidores potentes del citocromo P450 (CYP) 3A4 (p. ej., ritonavir y ketoconazol) en las 12 semanas anteriores a la selección 13. Inicio de una dieta de eliminación o alimentación elemental en los 30 días anteriores a la selección (la dieta debe permanecer estable después de firmar el FCI) 14. Nivel de cortisol en suero de la mañana (07:00 a 09:00 o tan cerca de ese intervalo como sea posible) ≤5 μg/dl (138 nmol/l) que no responde a la estimulación de ACTH: definido como un nivel de cortisol en suero <16 μg/dl (440 nmol/l) a los 60 minutos con una prueba de estimulación de ACTH que utiliza 250 μg de cosintropina administrada por vía intramuscular (es decir, un resultado anómalo en la prueba de estimulación de ACTH)
    15. Uso de inmunomoduladores biológicos en las 24 semanas anteriores a la selección (se permite inyección de insensibilización de la alergia o tratamiento oral siempre que el ciclo de tratamiento no se modifique durante el periodo del estudio) 16. Sujetos que hayan iniciado, interrumpido o cambiado la pauta posológica de antagonistas del receptor H2 de histamina, antiácidos o antihistamínicos para cualquier afección, como enfermedad de reflujo gastroesofágico en las 4 semanas anteriores a la endoscopia de cualificación. Si ya recibe estos fármacos, la dosis debe permanecer constante durante todo el estudio 17. Sujetos que hayan cambiado la pauta posológica de IBP en las 8 semanas previas a la endoscopia de aptitud. Si ya recibían IBP, la dosis debe mantenerse constante a lo largo de todo el studio 18. Infección con hepatitis B, hepatitis C o virus de inmunodeficiencia humana 19. Presentar hemorragia gastrointestinal o úlcera péptica activa documentada en las 4 semanas anteriores a la selección o introducir un nuevo periodo de estudio 20. Presentar infección crónica, como tuberculosis previa o activa, varicela o sarampión activos o ausencia de vacunación anterior contra el sarampión, las paperas y la rubéola. Los sujetos con exposición a tuberculosis o que vivan en zonas muy endémicas deben ser evaluados localmente para detectar tuberculosis antes de considerar su inclusión en el studio 21. Presentar inmunodepresión, inmunodeficiencia, neoplasia maligna, excepto las tratadas
    22. Cáncer de piel no melanoma o trastorno hemorrágico grave conocido 23. Tener antecedentes o presencia de enfermedad de Crohn, enfermedad celíaca u otra enfermedad inflamatoria del tracto gastrointestinal, incluida la gastroenteritis eosinofílica 24. Abuso actual de drogas según la opinión del investigador. 25. Abuso actual de alcohol según la opinión del investigador. 26. Pacientes que estén embarazadas, en período de lactancia o que pretendan quedarse embarazadas durante el estudio
    Refiéranse la lista completa de los criterios de exclusion en la seccion del protocolo "seleccion de sujetos" en la página 7.
    E.5 End points
    E.5.1Primary end point(s)
    Part A co-primary endpoints:
     Percentage of subjects who are histological responders (achieve ≤6 peak eos/HPF) at Week 12
     Mean change from baseline to Week 12 in number of dysphagia episodes

    Part B key endpoints:
     Percentage of APT-1011 responders in Part A who relapse histologically (>15 peak eos/HPF) by Week 52
     Mean change from Week 12 in Part A responders in number of dysphagia episodes at time of EGD at or before Week 52
    Criterios de valoración coprincipales de la parte A:
    Porcentaje de sujetos que tiene respuesta histológica (alcanzan ≤6 picos de eos/CGA) en la semana 12
    Cambio medio desde el inicio hasta la semana 12 en el número de episodios de disfagia

    Criterios de valoración principales de la parte B:
    Porcentaje de sujetos con respuesta a APT-1011 en la Parte A que tiene recidiva histológica (>15 picos de eos/CGA) en la semana 52
    Cambio medio desde la semana 12 en los sujetos con respuesta en la Parte A en el número de episodios de disfagia en el momento de la EGD en la semana 52 o antes
    E.5.1.1Timepoint(s) of evaluation of this end point
    Part A co-primary endpoints:
     at Week 12
     from baseline to Week 12

    Part B key endpoints:
     by Week 52 in Part A
     from Week 12 in Part A and at or before Week 52
    Criterios de valoración coprincipales de la parte A:
    en la semama 12
    desde el inicio hasta la semana 12
    Criterios de valoración principales de la parte B:
    en la semana 52 en la Parte A
    desde la semana 12 en la parte A y en o antes de la semana 52
    E.5.2Secondary end point(s)
    Part A secondary endpoints:
     Mean change from baseline in mean EREFs at Week 12
     Percentage of subjects who achieve <1 eos/HPF at Week 12
     Mean change from baseline in mean episode-level symptom burden (PROSE) at Week 12
     Mean change from baseline in mean episode-level severity (PROSE) at Week 12
     Mean change from baseline in mean eosinophils per HPF at Week 12
     Percentage of subjects who achieve <15 eos/HPF at Week 12
     Mean change from baseline in mean number of dysphagia-free days at Week 12

    Part B secondary endpoints:
     Mean change from Week 12 in Part A responders in mean EREF scores at time of EGD at or before Week 52
     Mean change from Week 12 in Part A responders in mean eosinophils per high power field at time of EGD at or before Week 52
     Mean change from Week 12 in Part A responders in episode-level symptom burden using the PROSE at time of EGD at or before Week 52
     Mean change from Week 12 in Part A responders in episode-level severity using the PROSE at time of EGD at or before Week 52
     Mean change from Week 12 in Part A responders in mean number of dysphagia-free days at time of EGD at or before Week 52
    Criterios de valoración secundarios de la parte A:
    Cambio medio con respecto al inicio en la EREFs media en la semana 12
    Porcentaje de sujetos que alcanzan <1 eos/CGA en la semana 12
    Cambio medio respecto al inicio en la media de carga de síntomas a nivel de episodio (PROSE) en la semana 12
    Cambio medio con respecto al inicio en la media de gravedad a nivel de episodio (PROSE) en la semana 12
    Cambio medio con respecto al inicio en la media de eosinófilos por CGA en la semana 12
    Porcentaje de sujetos que alcanzan <15 eos/CGA en la semana 12
    Cambio medio con respecto al inicio en el número medio de días sin disfagia en la semana 12
    Criterios de valoración secundarios de la parte B:
    Cambio medio desde la semana 12 en los sujetos con respuesta en la Parte A en las puntuaciones medias de EREF en el momento de la EGD en la semana 52 o antes
    Cambio medio desde la semana 12 en los sujetos con respuesta en la Parte A en los eosinófilos medios por campo de gran potencia en el momento de la EGD en la semana 52 o antes
    Cambio medio desde la semana 12 de los sujetos con respuesta en la Parte A en la carga de los síntomas a nivel de episodio utilizando los PROSE en el momento de la EGD en la semana 52 o antes
    Cambio medio desde la semana 12 en los sujetos con respuesta en la Parte A en la gravedad a nivel de episodio utilizando los PROSE en el momento de la EGD en la semana 52 o antes
    Cambio medio desde la semana 12 en los sujetos con respuesta en la Parte A en el número medio de días sin disfagia en el momento de la EGD en la semana 52 o antes
    E.5.2.1Timepoint(s) of evaluation of this end point
    Part A secondary endpoints:
     from baseline at Week 12
     at Week 12
     from baseline at Week 12
     from baseline at Week 12
     from baseline at Week 12
     at Week 12
     from baseline at Week 12

    Part B secondary endpoints:
     from Week 12 in Part A or before Week 52
     from Week 12 in Part A or before Week 52
     from Week 12 in Part A or before Week 52
     from Week 12 in Part A or before Week 52
     from Week 12 in Part A or before Week 52
    Criterios de valoración secundarios de la parte A:
    desde el inicio hasta la semana 12
    en la semama 12
    desde el inicio hasta la semana 12
    desde el inicio hasta la semana 12
    desde el inicio hasta la semana 12
    en la semama 12
    desde el inicio hasta la semana 12
    Criterios de valoración secundarios de la parte B:
    desde la semana 12 en la parte A o antes de la semana 52
    desde la semana 12 en la parte A o antes de la semana 52
    desde la semana 12 en la parte A o antes de la semana 52
    desde la semana 12 en la parte A o antes de la semana 52
    desde la semana 12 en la parte A o antes de la semana 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA11
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Germany
    Spain
    Switzerland
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days17
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 20
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 20
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 90
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 10
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state14
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 16
    F.4.2.2In the whole clinical trial 120
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    See protocol section treatment duration page 9
    Refieranse al protocolo seción duración del tratamiento en la página 9
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-04-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-04-03
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA